EMERGENT BIOSOLUTIONS INC. Cash and Cash Equivalents, Fair Value Disclosure
EMERGENT BIOSOLUTIONS INC. (EBS) had Cash and Cash Equivalents, Fair Value Disclosure of $32.72 million as of 2013-09-30, per its 10-Q filed 2013-11-08.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2013-11-08
- 2013-09-30: Cash and Cash Equivalents, Fair Value Disclosure $32.72M.
- 2013-06-30: Cash and Cash Equivalents, Fair Value Disclosure $36.32M.
- 2012-12-31: Cash and Cash Equivalents, Fair Value Disclosure $42.72M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2013-09-30 | $32.72M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $36.32M 10-Q · filed 2013-08-06 |
| 2012-12-31 | $42.72M 10-Q · filed 2013-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |